These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 19231673)
1. Litigation regarding tPA and stroke. Pilcher CA Ann Emerg Med; 2009 Mar; 53(3):404; author reply 404-5. PubMed ID: 19231673 [No Abstract] [Full Text] [Related]
2. [Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study]. Di Pasquale G Ital Heart J Suppl; 2000 Jul; 1(7):947-8. PubMed ID: 10935744 [No Abstract] [Full Text] [Related]
3. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues. Liang BA; Lew R; Zivin JA Arch Neurol; 2008 Nov; 65(11):1429-33. PubMed ID: 19001160 [TBL] [Abstract][Full Text] [Related]
4. Expectations for tPA is pathway to litigation. ED Manag; 2011 Feb; 23(2):18-9. PubMed ID: 21400969 [No Abstract] [Full Text] [Related]
5. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA. Ghandehari K; Zahed AP; Taheri M; Abbasi M; Gorjestani S; Ahmadi AM; Nahayati MA Int J Stroke; 2009 Aug; 4(4):236. PubMed ID: 19689746 [No Abstract] [Full Text] [Related]
6. Tissue plasminogen activator approved for stroke. Barber A; Gommans J N Z Med J; 2005 May; 118(1214):U1432. PubMed ID: 15886728 [No Abstract] [Full Text] [Related]
8. Thrombolysis for stroke: policy should be based on science, and not on politics, money or fear of malpractice. Hoffman JR Emerg Med Australas; 2006 Jun; 18(3):215-8. PubMed ID: 16712529 [No Abstract] [Full Text] [Related]
9. [Thrombolytic therapy for acute ischemic stroke]. Mori E Nihon Rinsho; 2006 Nov; 64 Suppl 8():33-7. PubMed ID: 17469531 [No Abstract] [Full Text] [Related]
10. Combined stroke trial data confirms that early treatment with thrombolytics improves outcomes. Rollins G Rep Med Guidel Outcomes Res; 2004 Apr; 15(7):8-9. PubMed ID: 15101394 [No Abstract] [Full Text] [Related]
11. Predicted impact of intravenous thrombolysis. Another trial is needed. Hoffman JR BMJ; 2000 Apr; 320(7240):1007. PubMed ID: 10809554 [No Abstract] [Full Text] [Related]
14. Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke. Liang BA; Zivin JA Ann Emerg Med; 2008 Aug; 52(2):160-4. PubMed ID: 18313798 [TBL] [Abstract][Full Text] [Related]
15. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Flaherty ML; Kissela B; Khatri P Neurology; 2007 Feb; 68(9):710-1; author reply 711. PubMed ID: 17328117 [No Abstract] [Full Text] [Related]
16. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Kurth T; Heuschmann PU; Walker AM; Berger K Neurology; 2007 Feb; 68(9):710; author reply 711. PubMed ID: 17325289 [No Abstract] [Full Text] [Related]
17. Thrombolysis for acute stroke: the incontrovertible, the controvertible, and the uncertain. Silbergleit R; Scott PA Acad Emerg Med; 2005 Apr; 12(4):348-51. PubMed ID: 15805327 [No Abstract] [Full Text] [Related]
18. Thrombolysis in acute cerebrovascular disease: indications and limitations. Hacke W; Ringleb P; Stingele R Thromb Haemost; 1999 Aug; 82(2):983-6. PubMed ID: 10605813 [No Abstract] [Full Text] [Related]
19. Thrombolytic therapy with alteplase for ischaemic stroke. Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701 [TBL] [Abstract][Full Text] [Related]
20. Use of tissue plasminogen activator to treat acute ischemic stroke. Alexandrov AW Crit Care Nurse; 2010 Oct; 30(5):77-8. PubMed ID: 20889516 [No Abstract] [Full Text] [Related] [Next] [New Search]